¶ÈÀÓ¾Ò²ð

2013ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Asami T, Saito Y, Whitford TJ, Makris N, Niznikiewicz M, McCarley RW, Shenton ME, Kubicki M ; Abnormalities of middle longitudinal fascicle and disorganization in patients with schizophrenia.Schizophrenia research ; 143(2-3)253-259,2013
  2. Kamijima K, Higuchi T, Ishigooka J, Ohmori T, Ozaki N, Kanba S, Kinoshita T, Koyama T, ADMIRE Study Group ; Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: A randomized, double-blind, placebo-controlled study (ADMIRE study).Journal of affective disorders ; 151(3)899-905,2013
  3. Kato M, Nonen S, Serretti A, Tetsuo S, Takekita Y, Azuma J, Kinoshita T ; 5-HTTLPR rs25531A>G differentially influence paroxetine and fluvoxamine antidepressant efficacy:A randomized-controlled trial.Journal of clinical psychopharmacology ; 33(1)131-132,2013
  4. Kato M, Chang CM ; Augmentation Treatments with Second-generation Antipsychotics to Antidepressants in Treatment-resistant Depression.CNS drugs ; 27(S1)S11-S19,2013
  5. Komoto K, Ha-Kawa S, Tanigawa N, Kinoshita T ; Two Adult Cases of Pulmonary Artery Sling.Internal medicine ; 52(11)1271-1272,2013
  6. Nishida K, Morishima Y, Yoshimura M, Isotani T, Irisawa S, Jann K, Dierks T, Strik W, Kinoshita T, Koenig T ; EEG microstates associated with salience and frontoparietal networks in frontotemporal dementia, schizophrenia and Alzheimer's disease.Clinical neurophysiology ; 124(6)1106-1114,2013
  7. Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, Okugawa G, Kinoshita T ; A 12-week Randomized, Open-label Study of Perospirone Versus Aripiprazole in the Treatment of Japanese Schizophrenia Patients.Progress in neuro-psychopharmacology & biological psychiatry ; 40:110-114,2013
  8. ²ÃÆ£Àµ¼ù, ÌÚ¼ÉÒ»Ë, ÌÚ¼ µ£, ¸¶ µ±Ê¸ ; ¤¦¤ÄÉ¡¦¤¦¤Ä¾õÂ֤δµ¼Ô¤Ë¤ª¤±¤ëParoxetine±ö»À±ö¿åÏÂʪ½üÊü¾û(¥Ñ¥­¥·¥ë®CR¾û)¤Ë´Ø¤¹¤ë°ÂÁ´À­¤ÈÍ­¸úÀ­¤Îɾ²Á¡Á¤¦¤ÄÉ¡¦¤¦¤Ä¾õÂ֤δµ¼Ô¤ËÂФ¹¤ë»ÈÍÑÀ®ÀÓÄ´ºº¤ÎÃæ´ÖÊó¹ð¡Á.ÌôÍý¤È¼£ÎÅ ; 41(8)749-764,2013
  9. Ë̱ºÍ´°ì, µÈ¼¶©»Ë, ¿¥ÅÄ͵¹Ô, ¹âÀ¥¾¡¶µ, ÌÚ²¼Íøɧ ; ¹ðÃΤòµñÈݤ·¤¿Î¾¿Æ¤È¾®»ù¤¬¤ó´µ¼Ô¤ÎÂбþ¤Ë¶ìθ¤·¤¿£±Îã.Àº¿À²Ê ; 22(2)233-238,2013
  10. Ë̱ºÍ´°ì, »°°æ ¹À, µÈ¼¶©»Ë, Pascual-Marqui RD, °ëë½ÓÌÀ, ÌÚ²¼Íøɧ ; ¤»¤óÌѤȤ¦¤ÄɤδÕÊ̤ËÆñ½Â¤·¤¿1Îã¤Ë¤ª¤±¤ëÄêÎÌǾÇȲòÀÏ.ÆüËÜÌôʪǾÇȳزñ»¨»ï ; 14(1)59-63,2013
  11. ¶áÆ£Âç»°¡¤¾®Åĸ¶½ÓÀ®¡¤°ÀÅļç°ì¡¤ÃÓ¿¬µÁδ¡¤²¼ÅÄ·ò¸ã¡¤¹â¶¶ ¾½¡¤ÃÝÆâʸ°ì¡¤Ä¹Ã«ÀîÄ«Ê桤ƣ¸¶½¤°ìϺ¡¤µÈÅľ﹧¡¤µÈ¼¶©»Ë¡¤ÅĻҵ×É× ; ÆüËÜÁí¹çɱ¡Àº¿À°å³Ø²ñ²ñ°÷¤ËÂФ¹¤ëǧÃξɿÇÎŤ˴ؤ¹¤ë¥¢¥ó¥±¡¼¥ÈÄ´ºº.Áí¹çɱ¡Àº¿À°å³Ø ; 25(2)171-177,2013
  12. ÖÖË̲µ± ; Åý¹ç¼ºÄ´¾É¤ËÂФ¹¤ëperospirone¤Èaripiprazole¤Î̵ºî°Ù³äÉÕÈæ³Ó»î¸³ Î×¾²¸ú²Ì¤ÈǦÍÆÀ­¤òÃæ¿´¤Ë.Î×¾²Àº¿ÀÌôÍý ; 16(1)136-139,2013
  13. µÈ¼¶©»Ë, À¾ÅÄ·½°ìϺ, ÖÖË̲µ±, ¹âÌî¸ç»Ë, »°°æ ¹À, Ë̱ºÍ´°ì, ²ÃÆ£Àµ¼ù, °ëë½ÓÌÀ, Pascual-Marqui RD, ÌÚ²¼Íøɧ ; ¸þÀº¿ÀÌô¤ÎÌôʪǾÇÈŪ¸¡Æ¤ sLORETA¤ÎÀµ¾ï¥Ç¡¼¥¿¥Ù¡¼¥¹¤è¤ë¹³Àº¿ÀÉÂÌô¤Î¾¯¿ôÎãͽÈ÷Ū¸¡Æ¤.ÆüËÜÌôʪǾÇȳزñ»¨»ï ; 14(1)45-49,2013
  14. µÈÌî¿¿µª, ²¬Â¼¹¨Èþ, ÌðÌî͵»Ò, ÃæÊ¿¶Ç»Ò, »³ËÜÆØ»Ò, ¿ù»³Í´É×, ¼¾åµ®±É, ¹âÌî È», µÈ¼¶©»Ë, ÌÚ²¼Íøɧ ; Éü¿¦º¤Æñ¤Ê¿À·Ð¾É¤ª¤è¤Ó¤¦¤ÄÉ´µ¼Ô¤Î¿´ÍýŪÆÃħ¡Á¤¦¤ÄÉÂ¥ê¥ï¡¼¥¯¥Ç¥¤¥±¥¢Ä̽ê¼Ô¤Î¿´Íý¸¡ºº¤«¤é¡Á.(ºâ)¥á¥ó¥¿¥ë¥Ø¥ë¥¹²¬Ëܵ­Ç°ºâÃĸ¦µæ½õÀ®Êó¹ð½¸ ; (24)97-102,2013

¥Ú¡¼¥¸TOP¤ØÌá¤ë

ÁíÀ⡦²òÀâ

  1. Han C, Yeh TL, Kato M, Sato S, Chang CM, Pae CU ; Management of Chronic Depressive Patients with Residual Symptoms.CNS drugs ; 27(S1)53-57,2013
  2. Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, Pae CU ; Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.Expert Rev Neurother ; 13(7)851-870,2013
  3. ²ÃÆ£Àµ¼ù ; ÁжËÀ­¤¦¤ÄɤÎÌôʪÎÅË¡.Àº¿À²Ê ; 22(1)64-73,2013
  4. ²ÃÆ£Àµ¼ù ; ¸ÄÊ̲½¼£ÎŤظþ¤±¤¿¤¦¤ÄɤΰäÅÁÌôÍý¸¦µæ¤Î¸½¾õ.°å³Ø¤Î¤¢¤æ¤ß ; 244(5)397-403,2013
  5. ²ÃÆ£Àµ¼ù ; ¥²¥Î¥à¾ðÊó¤Ë¤è¤ë¸ú²Ìͽ¬¡Á¼ÂÎ×¾²¤Ç¤Î²ÄǽÀ­¤ò¹Í¤¨¤Æ¤ß¤ë¡Á.Î×¾²ÌôÍý ; 44(2)117-122,2013
  6. ²ÃÆ£Àµ¼ù ; ¤¦¤Äɸ¦µæ¤Î¸½¾õ¾Ò²ð P-Åü¥¿¥ó¥Ñ¥¯¤ò¥³¡¼¥É¤¹¤ëABCB1°äÅÁ»Ò ǾÆâÇ»ÅÙ¥Þ¡¼¥«¡¼¤È¤·¤Æ¤Î²ÄǽÀ­.Depression Frontier ; 11(2)101-109,2013
  7. ÌÚ²¼Íøɧ, ÌÚ¼·ÄÃË, ¹â¶¶ Îå, ţȴÍøÌÀ, ²ÃÆ£Àµ¼ù ; ¹³¤¦¤ÄÌô¤Î¼£Îŷѳ¤ò¹Í¤¨¤ë.Pharma Medica ; 31(2)97-102,2013
  8. Ë̸µ ·ò, ÃæëÔèÃË, ÌÚ²¼Íøɧ ; Åö±¡µßÌ¿µßµÞ¥»¥ó¥¿¡¼¤Ë¤ª¤±¤ëÌôʪÃæÆÇ´µ¼Ô¤Ø¤ÎTriage DOA¸¡ºº¤Î¼Â»Ü¾õ¶·.Sysmex Journal ; 35(2)56-62,2013
  9. ÎëÌÚÊþ»Ò, »³²Ê Ëþ, ÎëÌÚ·Ä»Ò, ÇÏÞ¼Ëãͳ»Ò, Ãæ ÂÙ, ÎëÌںڼ»Ò, ËÙÆâËãÈþ, ¼é²°Ä¾¼ù, ÌÚ²¼Íøɧ ; û´üÎÏÆ°Àº¿ÀÎÅË¡²áÄø¡ÁÀº¿ÀÎÅË¡²áÄøQ¥»¥Ã¥È¤òÍѤ¤¤¿¸¡Æ¤¡Á.Àº¿ÀÎÅË¡ ; 39(6)907-915,2013
  10. ÎëÌÚÈþº´ ; ¡ÚÊݸÈÇ Ç§ÃξɤΤ³¤È¤¬¤ï¤«¤ëËÜ °å³ØÃμ±¤È¥±¥¢¤Î´ðËÜ¡ÛǧÃξɤοͤò¥±¥¢¤¹¤ë ´Ä¶­¤ÎÀ°È÷.¤ª¤Ï¤è¤¦21 ; 24(12)76-77,2013
  11. ÖÖË̲µ±, ÌÚ²¼Íøɧ ; ¿·µ¬¹³Àº¿ÀÉÂÌô³«È¯¤Î¸½¾õ¤ÈŸ˾.ÆüËÜÎ×à® ; 71(4)730-736,2013
  12. µÈ¼¶©»Ë ; ¡ÚÊݸÈÇ Ç§ÃξɤΤ³¤È¤¬¤ï¤«¤ëËÜ °å³ØÃμ±¤È¥±¥¢¤Î´ðËÜ¡Û¸¶°ø¼À´µ¤ÎÃ챤ò¿¼¤á¤è¤¦ ¥¢¥ë¥Ä¥Ï¥¤¥Þ¡¼·¿Ç§ÃξÉ.¤ª¤Ï¤è¤¦21 ; 24(12)18-21,2013
  13. µÈ¼¶©»Ë ; ¡ÚÊݸÈÇ Ç§ÃξɤΤ³¤È¤¬¤ï¤«¤ëËÜ °å³ØÃμ±¤È¥±¥¢¤Î´ðËÜ¡Û¸¶°ø¼À´µ¤ÎÃ챤ò¿¼¤á¤è¤¦ ·ì´ÉÀ­Ç§ÃξÉ.¤ª¤Ï¤è¤¦21 ; 24(12)22-25,2013
  14. µÈ¼¶©»Ë ; ¡ÚÊݸÈÇ Ç§ÃξɤΤ³¤È¤¬¤ï¤«¤ëËÜ °å³ØÃμ±¤È¥±¥¢¤Î´ðËÜ¡Û¸¶°ø¼À´µ¤ÎÃ챤ò¿¼¤á¤è¤¦ ¤½¤Î¾¤ÎǧÃξÉ.¤ª¤Ï¤è¤¦21 ; 24(12)34-37,2013

¥Ú¡¼¥¸TOP¤ØÌá¤ë

Ãø½ñ

  1. Okugawa G ; Cerebellum and schizophrenia -The cerebellum volume reduction theory of schizophrenia.Handbook of the cerebellum and cerebellar disorder ; (4)1907-1921 Springer New York,2013
  2. ¥Õ¥¡¥ó¥Ç¥ó¥Ü¥¹(´Æ½¤), ÈËËñ»»ÃË, »ÍËÜ͵»Ò(´ÆÌõ), ²¬Â¼¹¨Èþ¤Û¤«(ËÝÌõ¶¨ÎÏ) ; APA¿´Íý³ØÂ缭ŵ ; 1-1056ÇÝÉ÷´Û,2013
  3. ´ä´Öµª»Ò, ¿¥ÅÄ͵¹Ô, ´ß¾å·Ã»Ò, Ë̸ýͳ´õ, 𱩠ÆÆ, ×¢¾ï½¨¿Í, Ê¡ÅĤä¤È¤ß, ʡ¼ÏÂÈþ, Ëܲ°ÉßÈþÆà, »³ÅÄÈÞº»»Ò, ÏÂÅľÈÊ¿ ; µßÌ¿µßµÞ¥»¥ó¥¿¡¼¤Ë¤ª¤±¤ë¼«»¦Ì¤¿ë¼Ô»Ù±çQ&A½¸¡ÁÆþ±¡½é´ü¤«¤é»Ï¤Þ¤ë¥½¡¼¥·¥ã¥ë¥ï¡¼¥¯¡Á ; 1-107ÂçºåÉܼ«»¦Ì¤¿ë¼ÔÏ¢·È»Ù±ç»ö¶ÈôÅö¼Ô²ñµÄÊÔ,2013
  4. ²ÃÆ£Àµ¼ù ; ­µ.³°Íè¤Î¥¬¥¤¥É¥é¥¤¥ó¿ÇÎÅ¡Á¿ÇÃÇ¡¦´ÉÍý¡¦¼£ÎÅ¡Á Àº¿À¡¦¿´¿È°å³Ø¼À´µ 45¤¦¤ÄÉÂ.º£Æü¤Î¿ÇÎŤΤ¿¤á¤Ë ¥¬¥¤¥É¥é¥¤¥ó³°Íè¿ÇÎÅ2013 ; 394-402Æü·Ð¥á¥Ç¥£¥«¥ë³«È¯,2013
  5. ²ÃÆ£Àµ¼ù ; ­º.¤è¤¯¤ß¤é¤ì¤ëÀº¿À¼À´µ ÁжËÀ­¾ã³².¿À·Ð¡¦Àº¿À¼À´µ¼£Îťޥ˥奢¥ë ; ÆÃÊÌ(2)287-288ÆüËÜ°å»Õ²ñ,2013
  6. ÖÖË̲µ±, ²ÃÆ£Àµ¼ù ; Âè10¾Ï ¹³Àº¿ÀÉÂÌôÁªÂò¤Î¥¨¥Ó¥Ç¥ó¥¹.¹³Àº¿ÀÉÂÌô¥×¥é¥¯¥Æ¥£¥«¥ë¥¬¥¤¥É ; 122-135Ãæ³°°å³Ø¼Ò,2013

¥Ú¡¼¥¸TOP¤ØÌá¤ë

2012ǯ

¸¶ÃøÏÀʸ¡¿¾ÉÎãÊó¹ð

  1. Kato M, Nonen S, Serretti, A., Tetsuo S, Takekita Y, Azuma J, Kinoshita T. 5-HTTLPR rs25531A>G differentially influence paroxetine and fluvoxamine antidepressant efficacy: A randomized-controlled trial. Journal of Clinical Psychopharmacology 2012 Dec 28. [Epub ahead of print]
  2. Cardena E, Lehmann D, Faber PL, Jonsson P, Milz P, Roberto D. Pascual-Marqui ; EEG sLORETA FUNCTIONAL IMAGING DURING HYPNOTIC ARM LEVITATION AND VOLUNTARY ARM LIFTING. International Journal of Clinical and Experimental Hypnosis ; 60(1)31-53,2012
  3. Faber PL, Lehmann D, Tei S, Tsujiuchi T, Kumano H, Roberto D. Pascual-Marqui ; EEG source imaging during two Qigong meditations. Cognitive Processing ; 13(3)255-265,2012
  4. Kurose K, Hiratsuka K, Ishiwata K, Nishikawa J, Nonen S, Azuma J, Kato M, Wakeno M, Okugawa G, Kinoshita T, Kurosawa T, Hasegawa R, Saito Y ; Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry research ; 198(3)424-429,2012
  5. Lehmann D, Faber PL, Tei S, Roberto D. Pascual-Marqui, Milz P, Kochi K ; Reduced functional connectivity between cortical sources in five meditation traditions detected with lagged coherence using EEG tomography. Neuroimage ; 60(2)1574-1586,2012
  6. Sandmann P, Dillier N, Eichele T, Meyer M, Kegel A, Roberto D. Pascual-Marqui ; Visual activation of auditory cortex reflects maladaptive plasticity in cochlear implant users. Brain ; 135:555-568,2012
  7. Takekita Y, Kato M, Wakeno M, Sakai S, Suwa A, Nishida K, Okugawa G, Kinoshita T ; A 12-week Randomized, Open-label Study of Perospirone Versus Aripiprazole in the Treatment of Japanese Schizophrenia Patients. Progress in neuro-psychopharmacology & biological psychiatry ; 40:110-114,2012
  8. ÈÄÅ침¼ù, ¿ùËÜãºÈ, ÌÚ²¼Íøɧ ; ¡Ú­¶µßµÞ³°Íè¤ÇÁø¶ø¤¹¤ëÀº¿À¾É¾õ¡¦Àº¿À¾ã³²¡ÛQ8 ºª¿ç¾õÂ֤Ȥ﨤ì¹þ¤ß¤ÇÈÂÁ÷¤µ¤ì¤¿¶ÛÄ¥ÉÂÀ­ºªÌ¤δµ¼Ô¤Ø¤ÎÂбþ. µßµÞŽ¥½¸Ãæ¼£ÎÅ ; 24(1-2)50-55,2012
  9. Æ£°æ¹¯ÃË, ´äÅÄÃçÀ¸, ¹â¶¶À¶µ×, Àж¿²¬½ã, °ËÆ£½ç°ìϺ, °ËЮ²í¿Ã, Âçµ×ÊÝÁ±Ï¯, Â翹ůϺ, ÈøºêµªÉ×, ÌÚ²¼Íøɧ, ¾®»³ »Ê, ÎëÌÚƻͺ, Ãæ¹þϹ¬, Ãæ¼ ½ã, 𱩿¿°ì, Èõ¸ýµ±É§, Ê¿°ÂÎÉͺ, ¿åÌî²íʸ ; Àº¿À²Ê°å¤Î¥Ç¥ÝºÞ¤Ø¤Î¹½¤¨¡¢¼£Îžõ¶·¤Ë¤Ä¤¤¤Æ¤ÎÂ絬ÌÏ¥¢¥ó¥±¡¼¥ÈÄ´ºº¡ÁÆüÆÈÈæ³Ó·ë²Ì¤òÃæ¿´¤Ë¡Á. Î×¾²Àº¿ÀÌôÍý ; 15(5)797-810,2012
  10. ´äÅÄÃçÀ¸, Æ£°æ¹¯ÃË, ϵ¤Íµ»Ö, ¹â¶¶À¶µ×, Àж¿²¬½ã, °ËÆ£½ç°ìϺ, °ËЮ²í¿Ã, Âçµ×ÊÝÁ±Ï¯, Â翹ůϺ, ÈøºêµªÉ×, ÌÚ²¼Íøɧ, ¾®»³ »Ê, ÎëÌÚƻͺ, Ãæ¹þϹ¬, Ãæ¼ ½ã, 𱩿¿°ì, Èõ¸ýµ±É§, Ê¿°ÂÎÉͺ, ¿åÌî²íʸ ; ËÜË®¤Ë¤ª¤±¤ëÅý¹ç¼ºÄ´¾É¤ÎºÆȯͽËɤ˴ؤ¹¤ëǧ¼±¤È¼èÁȤߤμÂÂÖ¡ÁÅý¹ç¼ºÄ´¾ÉºÆȯͽËɸ¦µæ²ñ¥¢¥ó¥±¡¼¥ÈÄ´ºº512̾¤Î·ë²Ì¤è¤ê¡Á. Î×¾²Àº¿ÀÌôÍý ; 15(5)785-796,2012
  11. ÊÒ¾åůÌé, ¿¥ÅÄ͵¹Ô, ÌÚ²¼Íøɧ ; Remission, recovery¤òÌܻؤ¹¼£ÎŤˤª¤±¤ëaripiprazole¤ÎÍ­¸úÀ­¡ÁÅý¹ç¼ºÄ´¾É5¾ÉÎã¤ÎÎ×¾²Åª¸¡Æ¤¡Á. Î×¾²Àº¿ÀÌôÍý ; 15(1)85-91,2012
  12. Áýß·½¡ÍÎ, Åĸý¿Î»Î, ¿ùËÜãºÈ, ¾®ÅçÇîÇ·, ¾¾ËÜÁáÉÄ, ¾®Å縦ÂÀϺ, ¿·µÜ ¶½ ; áÖÄË¥³¥ó¥È¥í¡¼¥ë¤¬º¤Æñ¤Ç¤¢¤Ã¤¿½Ñ¸å¿À·Ð¾ã³²À­áÖÄˤ˥ߥ륿¥¶¥Ô¥ó¤¬Í­¸ú¤Ç¤¢¤Ã¤¿1¾ÉÎã. Ëã¿ì ; 61(9)1003-1005,2012
  13. ÖÖË̲µ±, ÅĶᰡÍö, Æ£»³²íÀ², À¾ÅÄ·½°ìϺ, ¿ùËÜãºÈ, ²ÃÆ£Àµ¼ù, µÈ¼¶©»Ë, ÌÚ²¼Íøɧ ; Blonanserin¤¬ÁÕ¸ù¤·¤¿Tourette¾ã³²¤Î1Îã. Àº¿À²Ê¼£ÎÅ³Ø ; 27(1)109-113,2012
  14. ÖÖË̲µ±, ºä°æ»ÖÈÁ, ¼ÅÄÃι¯, ¿¥ÅÄ͵¹Ô, ÅĶᰡÍö, µÈ¼¶©»Ë, ²ÃÆ£Àµ¼ù, ÌÚ²¼Íøɧ ; Âç³Øɱ¡³°Íè¤Ë¤ª¤±¤ërisperidoneÆøúÀ­Ãí¼ÍÀ½ºÞ¤Î»ÈÍѷи³¡ÁËýÀ­´üÅý¹ç¼ºÄ´¾É¤ª¤è¤Ó¼ºÄ´´¶¾ð¾ã³²´µ¼Ô57Îã¤ËÂФ¹¤ë6¥«·î´Ö¤ÎÎ×¾²Åª¸¡Æ¤¡Á. Áí¹çɱ¡Àº¿À°å³Ø ; 23(3)287-294,2012
  15. ÅÏîµÍ³²Â, ÅÄÃ潨ÌÀ, Roberto D. Pascual-Marqui, Ê¿ÅŬ°ì ; ¥ª¥É¥Ü¡¼¥ë²ÝÂê¤òÍѤ¤¤¿ÊÒƬÄË´µ¼Ô¤Î¿ë¹Ôµ¡Ç½É¾²Á. ÆüËÜÌôʪǾÇȳزñ»¨»ï ; 13(1)37-42,2012
  16. »³ºêµ×Èþ»Ò, µÈÌî¿¿µª, ÌÚ²¼Íøɧ, ¾®Ìî½ãÊ¿ ; Âç³ØÀ¸¤Ë¤ª¤±¤ëÂпͶ²ÉÝŪ¿´À­¡¢¤Õ¤ì¤¢¤¤¶²ÉÝŪ¿´À­¤Èξ¿Æ¤ÎÍÜ°éÂÖÅ٤ˤĤ¤¤Æ. ¿´ÍýÎ×¾²³Ø¸¦µæ ; 29(6)673-682,2012
  17. µÈÌî¿¿µª, ÎëÌÚÊþ»Ò, ËÙÆâËãÈþ, ÌÚ²¼Íøɧ ; »ùƸ»×½Õ´ü¤Î¿À·Ð¾É´µ¼Ô¤Ë¤ª¤±¤ëû´ü¿´ÍýÎÅË¡¡Á´ü´Ö¡¦²ó¿ô¸ÂÄꥻ¥Ã¥·¥ç¥ó¤Î»î¤ß¡Á. ¥á¥ó¥¿¥ë¥Ø¥ë¥¹²¬Ëܵ­Ç°ºâÃĸ¦µæ½õÀ®Êó¹ð½¸ ; (23)105-110,2012

¥Ú¡¼¥¸TOP¤ØÌá¤ë

ÁíÀ⡦²òÀâ

  1. Æ£»³²íÀ², ¾åÌîÀéÊæ, ¿¥ÅÄ͵¹Ô, ÌÚ²¼Íøɧ ; »ùƸ»×½Õ´ü³°Íè¤Ë¤ª¤±¤ëGID¡Á²ÈÄí´Ä¶­°ø¤Î¸ºß¤äȯã¾ã³²¤Îʻ¸¤¬µ¿¤ï¤ì¤ë¾ì¹ç¡Á. ºÇ¿·Àº¿À°å³Ø ; 17(2)129-133,2012
  2. ÊÒ¾åůÌé, ¿¥ÅÄ͵¹Ô, ÌÚ²¼Íøɧ ; À­Æ±°ìÀ­¾ã³²¿ÇÃǤˤª¤±¤ëµ¤Ê¬¾É¾õ¤Î¥¢¥»¥¹¥á¥ó¥È¤Î½ÅÍ×À­. ºÇ¿·Àº¿À°å³Ø ; 17(2)135-140,2012
  3. ²ÃÆ£Àµ¼ù ; ¥¹¥È¥ì¥¹¤È¥¨¥Ô¥¸¥§¥Í¥Æ¥£¥¯¥¹. ¤¦¤ÄÉÂselected papers ; 2(1)9-11,2012
  4. ²ÃÆ£Àµ¼ù ; ¤¦¤Äɤˤª¤±¤ë¹³¤¦¤ÄÌô¤ÎÈ¿±þͽ¬¤È»È¤¤Ê¬¤±¡ÁFrom Research to Clinical¡Á. Àº¿À¿À·Ð³Ø»¨»ï ; 114(5)589-600,2012
  5. ²ÃÆ£Àµ¼ù ; ¸þÀº¿ÀÌô¤È°ìÈÌÆâ²ÊÌô¤Î¼£ÎŸú²Ì¤òÀµ³Î¤ËÈæ³Ó¤¹¤ë¡Á¥á¥¿²òÀϤΥì¥Ó¥å¡¼¡Á. ¤¦¤ÄÉÂselected papers ; 2(2)9-11,2012
  6. ÌÚ²¼Íøɧ ; ¤¦¤ÄɤÎÊÑÁ«¤ÈºÇ¶á¤Î¹³¤¦¤ÄÌô¤ÎÆ°¸þ. ÂçºåÉÜÌô»¨»ï ; 63(11)46-50,2012
  7. ¾¾ËÜÍÎÊå, °¤Éôµ±É×, ÃÓÅÄ´±»Ê, ¿¥ÅÄ͵¹Ô, ¹¯ ½ã, º´Æ£½Ó¼ù, ÄÍÅÄ ¹¶, ¿Ë´Ö¹î¸Ê, ¾¾±ÊÀ齩, »³Æâ½Óͺ, ã·Æ£ÍøÏÂ, Á¤¿¹Ä¾ºÈ, ÃæÄÍ´´Ìé, ÆñÇÈÍ´»°Ïº, ÌÚ¸Ô·É͵ ; À­Æ±°ìÀ­¾ã³²¤Ë´Ø¤¹¤ë¿ÇÃǤȼ£ÎŤΥ¬¥¤¥É¥é¥¤¥ó(Âè4ÈÇ). Àº¿À¿À·Ð³Ø»¨»ï ; 114(11)1250-1266,2012
  8. ¿¥ÅÄ͵¹Ô, ÊÒ¾åůÌé, »³ÅÄÈÞº»»Ò, Æ£»³²íÀ², »³ÅÄ·½Â¤, ÌðÌî͵»Ò, ²¬Â¼¹¨Èþ, ÃæÊ¿¶Ç»Ò, µÈÌî¿¿µª, ÎëÌÚÈþº´, ÌÚ²¼Íøɧ ; À­Æ±°ìÀ­¾ã³²¤ÎÊñ³çŪ¼£ÎŤˤª¤¤¤ÆÀº¿À²Ê°å¤¬²Ì¤¿¤¹Ìò³ä. ºÇ¿·Àº¿À°å³Ø ; 17(2)113-119,2012
  9. ¿¥ÅÄ͵¹Ô ; ¿»ÜÀßÏ¢·È¤Î¹½ÃÛ. Àº¿À¿À·Ð³Ø»¨»ï ; 114(6)661-665,2012
  10. ºä°æ»ÖÈÁ, ÖÖË̲µ±, ²ÃÆ£Àµ¼ù, ÌÚ²¼Íøɧ ; ÁжËÀ­¾ã³²¤Î¼£ÎÅ ÁжËÀ­¾ã³²°Ý»ý´ü¤Ë¤ª¤±¤ëŬÀڤʼ£ÎÅ. Àº¿À²Ê ; 20(4)384-390,2012
  11. º´µ×´Ö¿®»ê, ²ÃÆ£Àµ¼ù ; ¥·¥ê¡¼¥º¤¦¤Äɼ£ÎźÇÁ°Àþ¡ÁÆüËܤ鳤¦¤ÄÌô¤â¥³¥ó¥È¥í¡¼¥ë¥É¥ê¥ê¡¼¥¹À½ºÞ¤Î»þÂå¤Ø¡Á. Æü·Ð¥á¥Ç¥£¥«¥ë ; web,2012
  12. º´µ×´Ö¿®»ê, ²ÃÆ£Àµ¼ù, ÌÚ¼ÉÒ»Ë, Æ£ÅÄ¿®ÌÀ ; Àº¿À¼À´µ¼£ÎŤËÍѤ¤¤é¤ì¤ëÆâÉþÌô¤Ø¤ÎControlled Release Technology¤ÎƳÆþ¤È¤½¤Î°ÕµÁ. Î×¾²Àº¿ÀÌôÍý ; 15(8)1387-1402,2012
  13. ¿ùËÜãºÈ, »³ÅÄÈÞº»»Ò, ¿¥ÅÄ͵¹Ô, ÈÄÅ침¼ù, ÀÄú˱§°Ê, ¹âÀ¥¾¡¶µ, ÃæëÔèÃË, ×¢¾ï½¨¿Í, ÏÂÅľÈÊ¿, ÔìÎɾ»»Ò, ¸¶¤ë¤ß»Ò, ÌÚ²¼Íøɧ ; ¼«»¦Âкö­µ¼«»¦Ì¤¿ë¼Ô¥±¥¢¤Î¸½¾õ ÂçºåÃÏ°è¤Ç¤Î¼è¤êÁȤߡÖÂçºåÉܼ«»¦Ì¤¿ë¼Ô¼ÂÂÖÄ´ºº»ö¶È¡×¤Ë¤Ä¤¤¤Æ. µßµÞ°å³Ø ; 36(7)759-762,2012
  14. ÖÖË̲µ±, ÌÚ²¼Íøɧ ; ¥È¥Ô¥é¥Þ¡¼¥È (¥È¥Ô¥Ê Topina). ºÇ¿·Àº¿À°å³Ø ; 17(4)357-363,2012
  15. »³ÅÄÈÞº»»Ò, ¿ùËÜãºÈ, ¿¥ÅÄ͵¹Ô, ÈÄÅ침¼ù, Ë̸µ ·ò, ÊÒ¾åůÌé, Æ£»³²íÀ², Ê¿Àɧ, ÌÚ²¼Íøɧ, ÃæëÔèÃË ; µßÌ¿µßµÞ¥»¥ó¥¿¡¼¤Ë¤ª¤±¤ë¼«»¦Í½ËÉ¡ÁºÆ´ë¿ÞͽËɤ˲̤¿¤¹PSW¤ÎÌò³ä¡Á. Áí¹çɱ¡Àº¿À°å³Ø ; 23(3)253-259,2012
  16. µÈ¼¶©»Ë, À¾ÅÄ·½°ìϺ, °ëë½ÓÌÀ, Æþß· Áï, »°°æ ¹À, Ë̱ºÍ´°ì, ÀÄú˱§°Ê, Roberto D. Pascual-Marqui, ÌÚ²¼Íøɧ ; ǾÇȤDz¿¤¬¤ï¤«¤ë¤«¡ÁÅý¹ç¼ºÄ´¾É¡Á. ÆüËÜÌôʪǾÇȳزñ»¨»ï ; 13(1)67-68,2012
  17. µÈÌî¿¿µª, »³ÅÄÈÞº»»Ò, ¿¥ÅÄ͵¹Ô, ÌÚ²¼Íøɧ ; À­Æ±°ìÀ­¾ã³²¤Î»Ù±ç¤Ë¤ª¤¤¤ÆÎ×¾²¿´Íý»Î¡¦Àº¿ÀÊÝ·òÊ¡»ã»Î¤¬²Ì¤¿¤¹Ìò³ä. ºÇ¿·Àº¿À°å³Ø ; 17(2)101-111,2012

¥Ú¡¼¥¸TOP¤ØÌá¤ë

Ãø½ñ

  1. ÀТʸ¿®, ÆâÅÄÍβð, ¿¥ÅÄ͵¹Ô, ÌÚ¸µ¹¯²ð, ¾®Ã«½Ó°ì, ³¤Ë¡¹¯Íµ, µÆÃϱɼ¡, °Èºî¹îÇ·, º´¡¹ÌÚ½ÕÌÀ, º´ÅÄÀ¯Î´, ¹â¶¶ÎÉÅö, ±Ê°æ ½ß, ±ÊÈø¸÷°ì, µ×Ëö¿­°ì, ¸ÅÀºÈ, ´ÝÌÐ ·ò ; ED¿ÇÎÅ¥¬¥¤¥É¥é¥¤¥ó(2012ǯÈÇ) ; 1-110 ¥ê¥Ã¥Á¥Ò¥ë¥á¥Ç¥£¥«¥ë,2012
  2. ²ÃÆ£Àµ¼ù, µÈ¼¶©»Ë ; ¡Ú20.Àº¿À²ÊµßµÞ¡Û¿À·Ð¾É¾õ¤òȼ¤¦Àº¿À¾É¾õ. º£Æü¤ÎÀº¿À¼À´µ¼£ÎÅ»Ø¿Ë ; 826-830 °å³Ø½ñ±¡,2012
  3. ²ÃÆ£Àµ¼ù ; ¡Ú6.¥²¥Î¥à¡Û¤¦¤Äɼ£ÎÅÈ¿±þÀ­¤òµ¬Äꤹ¤ëÍ×°ø¡¦°äÅÁ»Ò. µ¤Ê¬¾ã³²¤ÎÌôÍý¡¦À¸²½³Ø¡Á¤¦¤ÄɤÎǾÆâ¥á¥«¥Ë¥º¥à¸¦µæ:¿ÊÊâ¤ÈÄ©Àï¡Á ; 264-281 °åÌô¥¸¥ã¡¼¥Ê¥ë¼Ò,2012
  4. ²ÃÆ£Àµ¼ù ; ÌôʪÎÅË¡(2)µ¤Ê¬Ä´À°Ìô. Àº¿À²Ê¼£ÎÅ³Ø µ¤Ê¬¾ã³²¤Î¼£ÎÅ¥¬¥¤¥É¥é¥¤¥ó ; 27(S)169-176 (³ô)À±Ï½ñŹ,2012
  5. »°°æ ¹À, µÈ¼¶©»Ë, ÌÚ²¼Íøɧ ; Ìôʪ¤ÈÃæÆÇ. Ǿ¤È¤³¤³¤í¤Î¥×¥é¥¤¥Þ¥ê¥±¥¢ 5.°Õ¼±¤È¿ç̲ ; 236-246 ¥·¥Ê¥¸¡¼,2012
  6. ¿ùËÜãºÈ, »³ÅÄÈÞº»»Ò, ÀÄú˱§°Ê, ÈÄÅ침¼ù, ¿¥ÅÄ͵¹Ô, ¹âÀ¥¾¡¶µ, ÅĶᰡÍö, ÌÚ²¼Íøɧ, ÃæëÔèÃË, ×¢¾ï½¨¿Í, ÏÂÅľÈÊ¿, º´Æ£ ÆÆ, ´ä´Öµª»Ò, ½»ÅĽïÍý°Í, Ìî¾åÃÒ»Ò, ¹â¶¶ÍµÈþ, Ë̳ÑÍλÒ, Ê¡ÅĤä¤È¤ß, ×¢ÌîÆóÈþ, ÂÀÅÄ͵»Ò, â°æËþ§, °æÇÈÍ­µª»Ò, ±ä¸¶Ê¸½ï, Å£ÅÄ̯»Ò, ʡ¼ÏÂÈþ ; ÂçºåÉܼ«»¦Ì¤¿ë¼Ô¼ÂÂÖÄ´ººÊó¹ð½ñ ; 1-50 ÂçºåÉÜ/´ØÀ¾°å²ÊÂç³ØÁí¹ç°åÎÅ¥»¥ó¥¿¡¼,2012
  7. ¿ùËÜãºÈ, »³ÅÄÈÞº»»Ò ; °Õ¼±¾ã³²¤È´ÕÊ̤¬Æñ¤·¤¤Å¾´¹À­¾ã³²¤Î»öÎã(¤¤¤ï¤æ¤ë¥Ò¥¹¥Æ¥ê¡¼¤Î»öÎã)¡Áº£¸å¤ÎÀººº¡¦¼£ÎŤؤĤʤ°¤¿¤á¤ÎÊýά¡Á. µßµÞ°åÎŤˤª¤±¤ëÀº¿À¾É¾õɾ²Á¤È½é´ü¿ÇÎÅ £Ð£Å£ÅC¥¬¥¤¥É¥Ö¥Ã¥¯ ; 173-182 ¤Ø¤ë¤¹½ÐÈÇ,2012
  8. ÅĶᰡÍö, ÌÚ²¼Íøɧ ; ¡Ú12.ÌôºÞÀ­¡¦¾É¾õÀ­Àº¿À¾ã³²¡Û¹³É԰¡¦¿ç̲Ìô¤Ë¤è¤ëÀº¿À¾É¾õ. º£Æü¤ÎÀº¿À¼À´µ¼£ÎÅ»Ø¿Ë ; 455-458 °å³Ø½ñ±¡,2012

¥Ú¡¼¥¸TOP¤ØÌá¤ë